Simulations Plus

Total revenue of $15.8 million; Diluted Earnings Per Share (EPS) of $0.20;
Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67

More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science.

Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT

Simulations Plus to Present at Sidoti March Small-Cap Conference

Promising intellectual property resulting from the collaboration with Polish Academy of Sciences will be jointly owned for further development opportunities

Update includes enhanced PKanalix, Monolix, and Simulx modules

We announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.

Management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.

Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety

NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure

DSX is faster, more user-friendly, and scalable for high-performance computing

Initiates first steps in updated capital allocation strategy

Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift.
Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment

Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST

Project will focus on the development of a modeling & simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract

Ex-Anvisa General Manager will contribute to global regulatory strategies involving pharmacometrics

International organization’s mission is to close the gender gap in technology

Collaboration combines novel in vitro experimental methods and mechanistic modeling to accelerate development of orally inhaled drug products (OIDPs) and propose alternative approaches for bioequivalence

Fiscal 2022 revenue increased 16% year-over-year to $53.9 million
Diluted earnings per share increased 28% year-over-year to $0.60
Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%)